Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant

Subjects

Subjects :

Oncology
Cancer Research
medicine.medical_specialty
business.industry
medicine.medical_treatment
Daratumumab
Hematology
Newly diagnosed
medicine.disease
Internal medicine
Medicine
business
Multiple myeloma
Reduction (orthopedic surgery)
Dexamethasone
Lenalidomide
medicine.drug
Pain symptoms

Details

Language :

English

Database :

OpenAIRE

Journal :

Gries, K, Facon, T, Plesner, T, Usmani, S, Kumar, S, Orlowski, R Z, Bahlis, N J, Nahi, H, Mollee, P, Ramasamy, K, Roussel, M, Delforge, M, Karlin, L, Arnulf, B, Chari, A, Hulin, C, Weisel, K, He, J, Ho, K F, Wang, J, Van Rampelbergh, R, Uhlar, C, Kobos, R & Perrot, A 2019, ' Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant ', Clinical Lymphoma, Myeloma & Leukemia, vol. 19, no. 10 Supplement, pp. E225-E226 . https://doi.org/10.1016/j.clml.2019.09.375

Accession number :

edsair.doi.dedup.....46281553344506f13d135c999dbe8e38

Full Text :

https://doi.org/10.1016/j.clml.2019.09.375